Immuron Ltd. Files Form 6-K for March 2024
Ticker: IMRN · Form: 6-K · Filed: Mar 5, 2024 · CIK: 1660046
| Field | Detail |
|---|---|
| Company | Immuron LTD (IMRN) |
| Form Type | 6-K |
| Filed Date | Mar 5, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer
TL;DR
Immuron Ltd. filed a 6-K on March 5, 2024, updating SEC on its publications.
AI Summary
On March 5, 2024, Immuron Ltd. filed a Form 6-K to report a publication. The filing indicates that Immuron Limited is a foreign private issuer and is furnishing information to the SEC.
Why It Matters
This filing provides an update on Immuron Ltd.'s regulatory submissions, which could impact investor understanding of the company's ongoing operations and compliance.
Risk Assessment
Risk Level: low — The filing is a routine report of foreign private issuer information and does not contain significant financial or operational news.
Key Players & Entities
- Immuron Ltd. (company) — Registrant
- March 2024 (date) — Reporting period
- March 5, 2024 (date) — Filing date
- Form 6-K (document) — Filing type
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is filed by foreign private issuers to report information that they have made or are required to make public in their home country, or that they have distributed or are required to distribute to their security holders.
What is Immuron Ltd.'s primary business?
Immuron Ltd. is classified under the Pharmaceutical Preparations industry (SIC code 2834).
When is Immuron Ltd.'s fiscal year end?
Immuron Ltd.'s fiscal year ends on June 30.
Is Immuron Ltd. required to file annual reports on Form 20-F?
Yes, Immuron Ltd. indicates it files annual reports under cover of Form 20-F.
What specific information is Immuron Ltd. reporting in this March 2024 6-K?
The filing states that Immuron Limited published one announcement during the month of March 2024, but the specific details of that announcement are not included in the provided excerpt.
Filing Stats: 304 words · 1 min read · ~1 pages · Grade level 17.8 · Accepted 2024-03-04 21:19:29
Filing Documents
- ea0201193-6k_immuron.htm (6-K) — 13KB
- ea0201193ex99-1_immuron.htm (EX-99.1) — 11KB
- image_001.jpg (GRAPHIC) — 1KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- ex99-1_002.jpg (GRAPHIC) — 1KB
- ex99-1_003.jpg (GRAPHIC) — 5KB
- ex99-1_004.jpg (GRAPHIC) — 15KB
- 0001213900-24-019717.txt ( ) — 60KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- IMMURON LIMITED EXPLANATORY NOTE Immuron Limited (the “Company”) published one announcement (the “Public Notices”) to the Australian Securities Exchange on March 5, 2024 titled: - “Trading Halt” A copy of the Public Notice is attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 Trading Halt 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMURON LIMITED Date: March 5, 2024 By: /s/ Phillip Hains Phillip Hains Company Secretary 3